Patents by Inventor Marc B. Cox

Marc B. Cox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
    Patent number: 10434075
    Abstract: Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: October 8, 2019
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marc B. Cox, Jennifer Richer
  • FKBP52-SPECIFIC ANDROGEN RECEPTOR INHIBITOR, MJC13, FOR USE IN TREATING BREAST CANCER
    Publication number: 20170360725
    Abstract: Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicants: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Marc B. Cox, Jennifer Richer
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9782399
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 10, 2017
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, The Board of Regents of The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20160151350
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 2, 2016
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS
    Publication number: 20160030369
    Abstract: Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and/or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography/tandem mass spectrometry (LC/MS/MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventors: Huan Xie, Su Liang, Leonard M. Neckers, Marc B. Cox
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9233973
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 12, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, a California Corporation, Board of Regents, The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 8859207
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 14, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Texas at El Paso
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20120283215
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: September 14, 2010
    Publication date: November 8, 2012
    Applicants: The Regents of the University of California, a California Corporation, University of Texas at El Paso, Health and Human Services
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger, Robert Fletterick